Impact of Starting a Dolutegravir-based Regimen on HIV-1 Proviral DNA Reservoir Of Treatment Naïve and Experienced Patients (DRONE)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02370979
Recruitment Status : Unknown
Verified August 2015 by University Hospital, Strasbourg, France. Recruitment status was: Recruiting
This is a multi-center prospective study. The primary objective of DRONE study is to investigate the change of the size of HIV-1 DNA reservoir in blood from baseline to week 48 (W48) in participants treated by DTG-based regimen. Secondary objectives include: DTG pharmacokinetic and analysis of biomarkers of immune activation from baseline to W48.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 80 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Male or female aged from de 18 to 80 years
Patient starting a DTG-regimen
Patients agreeing to use methods of birthcontrol while on the study and during the 6 weeks after stopping DTG treatment
Signed and dated written informed consent is obtained from the subject or the subject's legal representative prior to screening
Women who are pregnant or breastfeeding
HBV or HCV coinfection
Participation in another clinical drug or device trial where the last dose of drug was within the past 30 days or an investigational medical device is currently implanted
An active AIDS-defining condition at Screening
Documented resistance to DTG
Allergy or intolerance to the study drugs or their components or drugs of their class
Any acute or verified Grade 4 laboratory abnormality (with the exception of Grade 4 lipids) at Screening.